论文部分内容阅读
背景已有研究报道抗高血压治疗的降压反应受肾素-血管紧张素-醛固酮系统基因变异的影响,但尚没有临床试验来证实是否血管紧张素转换酶(ACE)影响到不同的药物治疗与多种心血管危险因素及肾脏表型的关系。方法与结果采用双盲-阳性对照-随机抗高血压药物治疗试验,研究对象为年龄≥55岁,至少有一个以上心血管病危险因素的高血压患者。37939例研究对象被随机分到利尿剂(chlorthalidone),钙离子拮抗剂(amlodipine),血管紧张素转换酶抑制剂(Iisinopril),和α受体阻滞剂(doxazosin)四个药物治疗组,并随访4-8年;同时检测所有患者的ACE基因I/D多态性。首要观察终点包括致
Background It has been reported that the antihypertensive response to antihypertensive therapy is affected by the genetic variation of the renin-angiotensin-aldosterone system. However, there are no clinical trials to confirm whether angiotensin converting enzyme (ACE) affects different pharmacological treatments Relationship with Multiple Cardiovascular Risk Factors and Renal Phenotypes. Methods and Results A double-blind, positive control randomized antihypertensive trial was conducted in patients with hypertension ≥55 years and at least one cardiovascular risk factor. 37939 subjects were randomized to four drug-treated groups: chlorthalidone, amlodipine, angiotensin converting enzyme inhibitor (Iisinopril), and doxazosin All the patients were followed up for 4 to 8 years. ACE gene I / D polymorphism was also detected in all patients. The primary end point included induced